What is the appropriate method to switch a patient who was on Invega 156 mg intramuscular, then switched to Risperdal (risperidone) 2 mg twice daily, back to oral Invega (paliperidone)?

Switching from Risperdal 2mg BID to Oral Invega (Paliperidone)

Switch the patient to oral paliperidone ER 6 mg once daily, starting the day after the last dose of risperidone, without oral supplementation or cross-titration. This dose accounts for the fact that paliperidone is the active metabolite of risperidone, and the patient's current risperidone 4 mg/day total dose requires a higher paliperidone dose for equivalent therapeutic effect 1.

Dosing Rationale

The patient is currently on risperidone 4 mg/day total (2 mg BID). When switching from risperidone to paliperidone ER:

• Higher paliperidone doses are typically required compared to the risperidone dose due to pharmacokinetic differences 1
• Risperidone 4 mg/day is roughly equivalent to paliperidone ER 6 mg/day 2, 3
• The patient was previously on Invega 156 mg IM monthly (equivalent to approximately 6 mg/day oral risperidone), suggesting they tolerated and may require this higher exposure level 2

Switching Strategy

Initiate paliperidone ER the day after discontinuing risperidone 3. This approach is supported by:

• Paliperidone ER requires no dose titration and can be started at the target therapeutic dose 1, 4
• No oral supplementation is needed when initiating paliperidone ER 2, 3
• Risperidone has minimal anticholinergic and moderate sedative properties, allowing for relatively rapid discontinuation without significant withdrawal risk 1

Key Considerations

Avoid abrupt cross-titration or overlap - Since both medications work through the same active moiety (paliperidone), overlapping doses could lead to excessive dopamine D2 receptor blockade and increased extrapyramidal symptoms. The guideline emphasizes that switching should be informed by half-life and receptor profiles 5.

Dose Adjustment Options

After initiating paliperidone ER 6 mg daily:

• If inadequate response: Can increase to 9-12 mg daily after at least 4 days, with adjustments in 3 mg increments 4
• If tolerability issues: Can reduce to 3 mg daily, though this may be subtherapeutic given their previous exposure 4
• Therapeutic range: 3-12 mg daily, with 6 mg being the recommended starting dose for most patients 1

Monitoring

Assess treatment effectiveness within 4 weeks of the switch 5. The patient should show improvement in positive symptoms, functioning, and tolerability during this period. If significant symptoms persist after 4 weeks at therapeutic dose with good adherence, consider further dose adjustment or alternative strategies 5.

Common Pitfalls to Avoid

• Don't use the 1:1 mg conversion - Paliperidone requires higher doses than risperidone for equivalent effect
• Don't cross-taper unnecessarily - This increases complexity and risk of adverse effects without clear benefit when switching between risperidone and its active metabolite
• Don't start at 3 mg if the patient was stable on higher exposures - The patient's history of Invega 156 mg IM suggests they need robust dopamine blockade